IBOV 180,767.74 ▲ 1.89% IPSA 11,315.26 ▼ 1.14% IPC MEX 65,314.78 ▼ 0.18% MERVAL 3,040,031 ▲ 0.20% COLCAP 2,473.24 ▲ 1.99% BVL PERÚ 59,450.29 ▲ 0.01% USD/BRL5.15▼ 0.65% USD/MXN17.00▲ 0.03% USD/CLP936.84▲ 0.28% USD/COP3,162▼ 1.23% USD/PEN3.36▼ 0.24% USD/ARS1,513▲ 0.25% USD/UYU40.24▲ 0.68% USD/PYG5,873▲ 0.47% USD/BOB12.08▲ 3.98% USD/DOP58.55▲ 0.36% USD/CRC446.47▲ 1.09% USD/GTQ7.62▲ 1.63% USD/HNL26.84▲ 1.11% USD/NIO36.62▲ 0.14% USD/VES796.33▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.69▼ 0.06% EUR/BRL5.97▼ 0.63% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 180,767.74 ▲ 1.89% IPSA 11,315.26 ▼ 1.14% IPC MEX 65,314.78 ▼ 0.18% MERVAL 3,040,031 ▲ 0.20% COLCAP 2,473.24 ▲ 1.99% BVL PERÚ 59,450.29 ▲ 0.01% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Tuesday, September 1, 2026

Covid-19 Brazil

U.S. Agency Confirms Six Cases of Severe Allergic Reactions to Pfizer Vaccine

By · December 21, 2020 · 2 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

RIO DE JANEIRO, BRAZIL – Six people have developed a severe allergic reaction called anaphylaxis after receiving the covid-19 vaccine from Pfizer and BioNTech, said the CDC (Centers for Disease Control and Prevention) on Saturday, December 19th.

Some 113,000 people have already been vaccinated, according to the CDC, which is studying the reports of patients who presented some form of symptom after administration.

Some 113,000 people have already been vaccinated, according to the CDC, which is studying the reports of patients who presented some form of symptom after administration.
Some 113,000 people have already been vaccinated, according to the CDC. (Photo internet reproduction)
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

The agency said it is investigating the cause for the allergic reactions and how the six cases may be linked. Some of the individuals are from Alaska, but others are from other places, said Tom Clark, a CDC official who submitted data to the Advisory Committee on Immunization Practices (ACIP) whose members met yesterday to vote on another vaccine manufactured by Moderna.

The people affected are all adults under 65, and most have been hospitalized, promptly treated, and monitored, Clark said. The doses they received related to more than one production line, he added, suggesting that the reactions were not the result of a localized manufacturing problem. The CDC learned of all cases quickly through federal vaccine safety monitoring systems, said Clark.

U.S. begins logistics operation to distribute Moderna vaccine

Of the 112,807 people immunized registered in the health monitoring system by Friday, 3,150 reported symptoms after vaccination that prevented them from performing daily or labor activities. Most do not require medical care, Clark said, adding that the CDC is studying the reports for further details.

The ACIP endorsed the use of the Moderna vaccine on people aged 18 and older on Saturday, with panel members saying the benefits of inoculation outweighed the risks, considering that thousands of deaths were occurring daily in the U.S.

UK opened investigation

UK regulators said last week that people with a “significant history” of allergic reactions should not be administered Pfizer and BioNTech’s Covid-19 vaccine. The recommendation should continue while local authorities investigate two cases of allergic reactions that occurred on the first day of mass vaccination in the country. The alert may lead American and European authorities to restrict immunization to people without a history of severe allergic reactions.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.